You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

135 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Transplant Ineligible Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (subcut),
dexamethasone,
lenalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Cancer facts
Sep 2022
Cancer facts
Sep 2022
Guidelines and Advice
Status: Current
Sep 2022
Cancer facts
Oct 2022
Cancer facts
Oct 2022
Cancer facts
Nov 2022
Cancer facts
Nov 2022
Guidelines and Advice
Status: Current
ID: GL END 5-13
Version: N/A
Jun 2023
Guidelines and Advice
Status: Current
ID: PET 2022-2
Jun 2023
Drug
Other Name(s): Gazyva®
Quick Link(s): Drug Monograph, Patient Info Sheet
May 2022
Guidelines and Advice
Status: In-Review
ID: GL MOTAC-4
Version: 2
Jan 2022

Pages